1 completed, 1 recruiting, 1 terminated. 1 Not applicable, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow galsulfase: new trials by email Literature Review of galsulfase trials Research Report on galsulfase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders) Aldurazyme (laronidase) - MPS I, MPS II | Phase 1 | Recruiting | University of California, San Francisco | 10 | 2021-07-01 | 2026-03-17 |
| Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome Naglazyme® - Maroteaux-Lamy Syndrome | Not applicable | Terminated | Masonic Cancer Center, University of Minnesota | 1 | 2016-01-26 | 2020-12-23 |
| A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI Naglazyme - Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome | Phase 4 | Completed | BioMarin Pharmaceutical | 4 | 2006-05-01 | 2011-07-22 |
Mucopolysaccharidosis VI (3) · Gaucher Disease (1) · Mucopolysaccharidosis IV (1) · Mucopolysaccharidosis VII (1) · Sudden Infant Death (1) · Wolman Disease (1)
BioMarin Pharmaceutical (1) · Masonic Cancer Center, University of Minnesota (1) · University of California, San Francisco (1)
United States (3) · France (1) · Portugal (1)
Celeste Decker, MD (1) · Elizabeth Braulin, M.D. (1) · Tippi MacKenzie, MD (1)
PMID 15324318, PMID 19948615, PMID 21637107, PMID 23510062, PMID 24108527, PMID 28374935, PMID 28657663, PMID 30337566, PMID 32102934, PMID 33775523, PMID 37955580, PMID 39891377, PMID 9918480